中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2014年
7期
1492-1494
,共3页
胆管癌%肿瘤%环氧化酶-2%白细胞介素-6%前列腺素E2
膽管癌%腫瘤%環氧化酶-2%白細胞介素-6%前列腺素E2
담관암%종류%배양화매-2%백세포개소-6%전렬선소E2
Cholangiocarcinoma%Tumor%Cyclooxygenase-2%Interleukin-6%Prostaglandin E2
目的 观察环氧合酶-2 (COX-2)选择性抑制剂NS-398联合白细胞介素-6(IL-6)抗体对人肝门胆管癌QBC939细胞的增殖抑制及降低前列腺素E2(PGE2)含量的协同作用.方法 不同浓度NS-398(25、50、100μmol/L)、IL-6抗体(0.1、1.0、l0.0 mg/L)及联合用药(NS-398 100 μmol/L+ IL-6抗体10 mg/L)作用于QBC939细胞24、48、72 h后,细胞计数试剂盒(CCK-8)法测定细胞增殖抑制率,酶联免疫吸附试验(ELISA)法检测细胞PGE2含量.结果 不同浓度的NS-398、IL-6抗体对QBC939细胞均有抑制作用,且联合效果明显优于单药,各组与对照组比较差异均有统计学意义(P ＜0.05);ELISA分析:NS-398(100μmol/L)、IL-6抗体(10 mg/L)、联合组作用细胞72 h后每孔PGE2含量分别为(25.606±5.676)、(36.454±6.444)、(18.223±4.168)ng,与阴性对照组每孔(106.781±12.423)ng比较差异均有统计学意义(P＜0.05).结论 NS-398和IL-6抗体均有抑制人肝门胆管癌QBC939细胞增殖的作用,亦能降低细胞PGE2的含量,作用具有浓度、时间依赖性且联合作用更强.
目的 觀察環氧閤酶-2 (COX-2)選擇性抑製劑NS-398聯閤白細胞介素-6(IL-6)抗體對人肝門膽管癌QBC939細胞的增殖抑製及降低前列腺素E2(PGE2)含量的協同作用.方法 不同濃度NS-398(25、50、100μmol/L)、IL-6抗體(0.1、1.0、l0.0 mg/L)及聯閤用藥(NS-398 100 μmol/L+ IL-6抗體10 mg/L)作用于QBC939細胞24、48、72 h後,細胞計數試劑盒(CCK-8)法測定細胞增殖抑製率,酶聯免疫吸附試驗(ELISA)法檢測細胞PGE2含量.結果 不同濃度的NS-398、IL-6抗體對QBC939細胞均有抑製作用,且聯閤效果明顯優于單藥,各組與對照組比較差異均有統計學意義(P ＜0.05);ELISA分析:NS-398(100μmol/L)、IL-6抗體(10 mg/L)、聯閤組作用細胞72 h後每孔PGE2含量分彆為(25.606±5.676)、(36.454±6.444)、(18.223±4.168)ng,與陰性對照組每孔(106.781±12.423)ng比較差異均有統計學意義(P＜0.05).結論 NS-398和IL-6抗體均有抑製人肝門膽管癌QBC939細胞增殖的作用,亦能降低細胞PGE2的含量,作用具有濃度、時間依賴性且聯閤作用更彊.
목적 관찰배양합매-2 (COX-2)선택성억제제NS-398연합백세포개소-6(IL-6)항체대인간문담관암QBC939세포적증식억제급강저전렬선소E2(PGE2)함량적협동작용.방법 불동농도NS-398(25、50、100μmol/L)、IL-6항체(0.1、1.0、l0.0 mg/L)급연합용약(NS-398 100 μmol/L+ IL-6항체10 mg/L)작용우QBC939세포24、48、72 h후,세포계수시제합(CCK-8)법측정세포증식억제솔,매련면역흡부시험(ELISA)법검측세포PGE2함량.결과 불동농도적NS-398、IL-6항체대QBC939세포균유억제작용,차연합효과명현우우단약,각조여대조조비교차이균유통계학의의(P ＜0.05);ELISA분석:NS-398(100μmol/L)、IL-6항체(10 mg/L)、연합조작용세포72 h후매공PGE2함량분별위(25.606±5.676)、(36.454±6.444)、(18.223±4.168)ng,여음성대조조매공(106.781±12.423)ng비교차이균유통계학의의(P＜0.05).결론 NS-398화IL-6항체균유억제인간문담관암QBC939세포증식적작용,역능강저세포PGE2적함량,작용구유농도、시간의뢰성차연합작용경강.
Objective To examine the synergistic effect of NS-398 [a specific cyclooxygenase-2 (COX-2) inhibitor] and intedeukin-6 (IL-6) antibody on proliferation inhibition and prostaglandin E2(PGE2) levels of Hilar cholangiocarcinoma (HCCA) cell line QBC939.Methods QBC939 cells were divided into 25,50 and 100 μmol/L NS-398 groups.0.1,1.0,10.0 mg/L IL-6 antibody groups and NS-398 100 μmol/L + IL-6 antibody 10 mg/L combination groups.The cells were treated for 24,48,72 h.The proliferation-inhibitory activity of QBC939 cells were detected by cell counting kit-8 (CCK-8).The PGE2 levels in the supernatant of cultured cells were quantitated by ELISA.Results After treated with NS-398 and IL-6 antibody respectively or in combination,cells proliferation were obviously inhibited,and the role in combined treatment groups was more significant than monotherapy groups compared with the negative control group (P＜0.05).ELISA showed that:After 72 h,the PGE2 value of NS-398 100 μmol/L group,IL-6 antibody 10 mg/L group and NS-398 100 μmol/L + IL-6 antibody 10 mg/L group were (25.606 ± 5.676) ng/well,(36.454 ± 6.444) ng/well,(18.223 ± 4.168) ng/well and respective-ly compared with the negative control group (106.781 ± 12.423) ng/well (P ＜ 0.05).Conclusion NS-398 and IL-6 antibody had inhibitory effects on the growth of HCCA cell line QBC939,and they could inhibit the expressions of PGE2 in QBC939 cells in a dose and time dependent manner.And the combination inhibitory effect was more apparent.
